Related Experiment Video

Updated: Jan 29, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

380

Zipalertinib-A Novel Treatment Opportunity for Non-Small Cell Lung Cancers with Exon 20 Insertions and Uncommon EGFR

Wolfram C M Dempke1, Klaus Fenchel2, Niels Reinmuth3

  • 1University Hospital, LMU Munich, Grosshadern Campus, 81377 Munich, Germany.

Cancers
|January 28, 2026
PubMed

Insights

Zipalertinib shows promise for non-small cell lung cancer (NSCLC) patients with uncommon EGFR mutations and exon 20 insertions. Ongoing trials are evaluating its efficacy in various settings, including first-line therapy and brain metastases.

Area of Science:

  • Oncology
  • Pharmacology
  • Genetics

Background:

  • Non-small cell lung cancer (NSCLC) has high mortality, with EGFR alterations driving treatment advances.
  • Uncommon EGFR mutations and exon 20 insertions in NSCLC present poor prognoses, necessitating novel therapies.
  • Current EGFR tyrosine kinase inhibitors (TKIs) show limited efficacy against these specific alterations.

Purpose of the Study:

  • To evaluate the efficacy of zipalertinib, a novel EGFR TKI, against uncommon EGFR mutations and exon 20 insertions in NSCLC.
  • To assess zipalertinib's activity in various clinical settings, including first-line therapy, brain metastases, and adjuvant treatment.
  • To explore the role of zipalertinib, alone or in combination, within the NSCLC treatment landscape.

Main Methods:

  • Zipalertinib, an oral, irreversible EGFR TKI with a unique pyrrolopyrimidine structure, was developed.
  • Preclinical activity was assessed against classical and uncommon EGFR mutations, including exon 20 insertions.
  • Clinical activity is being evaluated in multiple NSCLC trials (REZILIENT 1-4), including first-line therapy and brain metastases.

Main Results:

  • Zipalertinib demonstrates activity against classical EGFR mutations (del19, L858R) and some uncommon mutations (T790M, G719X, S768I, L861Q).
  • The compound shows predominant activity in NSCLC cells with EGFR exon 20 insertions.
  • Preliminary clinical data from REZILIENT trials indicate significant activity in patients with uncommon mutations, exon 20 insertions, and brain metastases.

Conclusions:

  • Zipalertinib is a promising novel EGFR TKI for NSCLC patients with challenging mutations, particularly exon 20 insertions.
  • Ongoing clinical trials are crucial for establishing zipalertinib's role in first-line, combination, and adjuvant therapies.
  • Further evidence is needed to define the therapeutic impact of zipalertinib compared to other agents and chemotherapy combinations.
Keywords:
NSCLCexon 20 insertionstargeted therapyuncommon mutationszipalertinib

More Related Videos

Detecting Somatic Genetic Alterations in Tumor Specimens by Exon Capture and Massively Parallel Sequencing11:02

Detecting Somatic Genetic Alterations in Tumor Specimens by Exon Capture and Massively Parallel Sequencing

Published on: October 18, 2013

19.9K
Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

9.3K

Related Concept Videos

Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
14.9K
Mutations01:39

Mutations

Overview
94.4K
Mutations01:35

Mutations

Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
44.5K
Exon Recombination02:32

Exon Recombination

The evolution of new genes is critical for speciation. Exon recombination, also known as exon shuffling or domain shuffling, is an important means of new gene formation. It is observed across vertebrates, invertebrates, and in some plants such as potatoes and sunflowers. During exon recombination, exons from the same or different genes recombine and produce new exon-intron combinations, which might evolve into new genes. 
Exon shuffling follows “splice frame rules.” Each exon...
4.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Viral Mutations00:36

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
39.9K